CMS Comment Letter on Proposed Coverage Decision, February 2022

CMS's January announcement proposes to cover the class of anti-amyloid mAb treatments for AD under a coverage with evidence development (CED) framework in randomized controlled trials. Our recommendations describe opportunities for CMS to refine their proposed coverage decision in light of the evolving body of evidence for mAb treatments and to address the priorities of patient access, equity, and further needed evidence development.